Smith & Nephew’s (SN) Buy Rating Reiterated at Shore Capital Group

Shore Capital Group restated their buy rating on shares of Smith & Nephew (LON:SN) in a research note published on Tuesday morning,Digital Look reports. Shore Capital Group currently has a GBX 1,000 target price on the stock.

Other equities research analysts also recently issued reports about the stock. UBS Group reissued a “neutral” rating and issued a GBX 1,300 price target on shares of Smith & Nephew in a research note on Tuesday, May 5th. Citigroup cut shares of Smith & Nephew to a “buy” rating in a research report on Friday, July 10th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 1,350 target price on shares of Smith & Nephew in a report on Monday, June 29th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 1,400 target price on shares of Smith & Nephew in a research report on Thursday, June 11th. Finally, Jefferies Financial Group restated a “buy” rating and set a GBX 2,760 price target on shares of Smith & Nephew in a research note on Thursday, May 21st. Four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of GBX 1,340.11.

Smith & Nephew Trading Down 0.5%

Shares of SN opened at GBX 1,119 on Tuesday. The firm has a 50-day moving average of GBX 1,130.43 and a 200-day moving average of GBX 1,198.67. The company has a debt-to-equity ratio of 62.90, a quick ratio of 0.84 and a current ratio of 2.57. The stock has a market cap of £12.27 billion, a price-to-earnings ratio of 40.29, a P/E/G ratio of 0.46 and a beta of 0.68.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.